Holen Sie sich die Stockscreener-App
28.50
0.30%
-0.07
Handel nachbörslich:
28.50
Schlusskurs vom Vortag:
$28.57
Offen:
$28.67
24-Stunden-Volumen:
202.53K
Relative Volume:
0.46
Marktkapitalisierung:
$1.25B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+2.24%
1M Leistung:
+22.28%
6M Leistung:
+235.12%
1J Leistung:
+0.00%
1-Tages-Spanne:
$28.20
$29.09
1-Wochen-Bereich:
$26.63
$29.66
52-Wochen-Spanne:
$6.71
$29.66
Maze Therapeutics Inc Stock (MAZE) Company Profile
Firmenname
Maze Therapeutics Inc
Sektor
Branche
Telefon
(650) 850-5070
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Vergleichen Sie MAZE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
28.50 | 1.25B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-02 | Eingeleitet | BTIG Research | Buy |
| 2025-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-08 | Eingeleitet | Wedbush | Outperform |
Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten
What is the fair value of Maze Therapeutics Inc. stock nowJuly 2025 Highlights & Free Risk Controlled Daily Trade Plans - newser.com
Can Maze Therapeutics Inc. stock beat market expectations this quarterProduct Launch & High Return Trade Opportunity Guides - newser.com
Why Maze Therapeutics Inc. is moving todayQuarterly Profit Summary & Real-Time Buy Zone Alerts - newser.com
Weiss Ratings Reaffirms "Sell (D)" Rating for Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Can a trend reversal in Maze Therapeutics Inc. lead to recovery2025 Fundamental Recap & Capital Protection Trade Alerts - newser.com
How to use a screener to detect Maze Therapeutics Inc. breakoutsWall Street Watch & Free Daily Entry Point Trade Alerts - newser.com
Pompe Disease Market Research 2025: Treatment, Route of Administration, and Region Analysis and Forecast to 2035 Featuring Amicus Therapeutics, Astellas, BioMarin, Maze Therapeutics, Oxyrane ParasailResearchAndMarkets.com - The AI Journal
Maze Therapeutics (NASDAQ:MAZE) Reaches New 1-Year HighWhat's Next? - MarketBeat
Maze Therapeutics Appoints Herve Hoppenot as Board Chairman - MarketScreener
What technical models suggest about Maze Therapeutics Inc.’s comeback2025 Major Catalysts & Long Hold Capital Preservation Plans - newser.com
Maze Therapeutics appoints Hervé Hoppenot as chairman of the board - Investing.com
Maze Therapeutics Appoints Hervé Hoppenot as Chairman - TipRanks
Maze Therapeutics appoints Hervé Hoppenot as board chairman - Investing.com India
Maze Therapeutics appoints Hervé Hoppenot as board chairman By Investing.com - Investing.com Australia
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors - GlobeNewswire
Detecting price anomalies in Maze Therapeutics Inc. with AI2025 Sector Review & Growth Focused Stock Pick Reports - newser.com
Predicting Maze Therapeutics Inc. trend using moving averages2025 Top Decliners & Verified Swing Trading Watchlist - newser.com
Maze Therapeutics (MAZE): Assessing Current Valuation Following a 78% Monthly Share Price Surge - Sahm
Maze Therapeutics (MAZE): Assessing Valuation After 78% 30-Day Share Price Surge - Yahoo Finance
What drives Maze Therapeutics Inc stock priceSupport Level Holds & Exceptional Profit Trading - earlytimes.in
Developing predictive dashboards with Maze Therapeutics Inc. dataWall Street Watch & Low Risk Entry Point Guides - newser.com
BTIG Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $37 - 富途牛牛
Maze Therapeutics Stock Just Shot Up 24% Pre-Market Today – Here’s What Happened - MSN
Goldman Sachs Group Inc. Makes New $145,000 Investment in Maze Therapeutics, Inc. $MAZE - Defense World
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 5.2%Should You Sell? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $37.00 at JPMorgan Chase & Co. - MarketBeat
J.P. Morgan Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Raises Target Price to $37 - 富途牛牛
What analysts say about Maze Therapeutics Inc stockEarnings Beat Highlights & Outstanding Trading Tips - earlytimes.in
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 4.4%Still a Buy? - MarketBeat
Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)
Es liegen keine Finanzdaten für Maze Therapeutics Inc (MAZE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):